Cover Image

Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients

We analyzed serially collected serum samples from healthy adults who underwent BNT162b2 vaccination to elucidate the association between spike (S)-IgG antibody titers determined by ELISA using the WHO international standard (NIBSC code 20/136) and neutralizing antibody titers against three live SARS...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yuki Higashimoto (Author), Kei Kozawa (Author), Hiroki Miura (Author), Yoshiki Kawamura (Author), Masaru Ihira (Author), Hiroyuki Hiramatsu (Author), Ryota Suzuki (Author), Kei Haga (Author), Reiko Takai-Todaka (Author), Akihito Sawada (Author), Kazuhiko Katayama (Author), Tetsushi Yoshikawa (Author)
Format:	Book
Published:	Taylor & Francis Group, 2022-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Rotavirus genotypes and clinical outcome of natural infection based on vaccination status in the post-vaccine era
by: Kei Kozawa, et al.
Published: (2022)

Future Perspective for ALK-Positive Anaplastic Large Cell Lymphoma with Initial Central Nervous System (CNS) Involvement: Could Next-Generation ALK Inhibitors Replace Brain Radiotherapy for the Prevention of Further CNS Relapse?
by: Makito Tanaka, et al.
Published: (2023)

Reactive arthritis following COVID-19 vaccination with BNT162b2
by: Emily Lebowitz, MD, et al.
Published: (2022)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
by: Francesca Fortunato, et al.
Published: (2023)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
by: Chi-Yan Lam, et al.
Published: (2023)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021)

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan
by: Mitsuhiro Nagano, et al.
Published: (2024)

BNT162b2 mRNA Vaccine-Induced Immune Response in Oral Fluids and Serum
by: Chaminda Jayampath Seneviratne, et al.
Published: (2023)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
by: Gili Regev-Yochay, et al.
Published: (2021)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer-BioNTech) COVID‐19 vaccination
by: Akihiro Matsubara, et al.
Published: (2021)

Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
by: Shanti Pather, et al.
Published: (2023)

B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients
by: Younes Bathish, et al.
Published: (2024)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
by: Bei Wang, et al.
Published: (2021)

BNT162b2 immunization-related myocarditis in adolescents and consequent hospitalization: Report from a medical center
by: Chen-Wei Yen, et al.
Published: (2023)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
by: Rumiko Shimazawa, et al.
Published: (2021)

Effectiveness of BNT162b2 COVID-19 vaccine among healthcare workers of a large hospital, Milan, Italy
by: Dario Consonni, et al.
Published: (2022)

Short-term side effects of BNT162b2 vaccine in primary care settings in Qatar: a retrospective study
by: Sami Abdeen, et al.
Published: (2024)

Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases
by: Richard Paul Junghans
Published: (2021)

Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data
by: Frank van den Ouweland, et al.
Published: (2024)

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
by: Michael Kwan Leung Yu, et al.
Published: (2024)

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
by: Shir Azrielant, et al.
Published: (2024)

Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study
by: Angel Paternina-Caicedo, et al.
Published: (2022)

Efectividad de la vacuna BNT162b2 en el personal del Centro de Salud de Jávea
by: María José Mulet Pons, et al.
Published: (2022)

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
by: Ai-Min Hui, et al.
Published: (2022)

Allergy to PEG (polyethylene glycol) - sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2
by: Bernadette Eberlein, et al.
Published: (2024)

Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers
by: Salvatore Zaffina, et al.
Published: (2021)

Coincidence of BNT162b2 mRNA COVID-19 vaccination and hashimoto thyroiditis presenting as atrioventricular block: Causality or casualty
by: Kuang-Jen Chien, et al.
Published: (2023)

Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes
by: Hamdi Cihan Emeksiz, et al.
Published: (2023)

Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
by: Giulia Vivaldi, et al.
Published: (2022)

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
by: Suvimol Niyomnaitham, et al.
Published: (2022)

Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
by: Xiaotian Wu, MBBS, MRCP, MMed, et al.
Published: (2022)

Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis
by: Tingting Li, et al.
Published: (2022)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
by: Toshio Naito, et al.
Published: (2022)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
by: Andrea Lombardi, et al.
Published: (2021)

Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
by: Rana Shibli, et al.
Published: (2021)

Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
by: Clara Udaondo, et al.
Published: (2022)

COVID-19 mRNA BNT162b2 vaccine safety and antibodies level among healthcare workers at Centre Hospitalier du Nord
by: Rosabelle Chedid, et al.
Published: (2022)

Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases
by: Pedro Rodríguez-Jiménez, MD, PhD, et al.
Published: (2021)

Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine
by: Rachael K. Raw, et al.
Published: (2023)